Dr. Mitchell Levine is a professor in McMaster University’s Department of Health Research Methods, Evidence and Impact (HEI) and is the assistant dean for the graduate school program in Health Research Methodology in the Faculty of Health Sciences. He is also a professor in the Department of Medicine, Division of Clinical Pharmacology, and is a consultant physician at St. Joseph’s Healthcare Hamilton. He is the director of the Centre for Evaluation of Medicines, Father Sean O'Sullivan Research Centre, at St. Joseph's Healthcare Hamilton. In February 2018 he was appointed chair of Canada’s Patented Medicine Prices Review Board (PMPRB) by her Excellency, the Governor General in Council, having served as the vice-chair since 2011.
Dr. Levine received his medical degree from the University of Calgary, which was followed by postgraduate training in Internal Medicine (FRCPC) and Clinical Pharmacology at the University of Toronto. He received an MSc degree in Clinical Pharmacology at the University of Toronto and an MSc degree in Clinical Epidemiology from McMaster University.
- Developing methods to obtain maximum value from drug therapy resources.
- Assessing prescription drug use in the community
- Assessing risk-benefit in drug therapies
Cossette B, Éthier JF, Joly-Mischlich T, Bergeron J, Ricard G, Brazeau S, Caron M, Germain O, Payette H, Kaczorowski J, Levine M. Reduction in potentially inappropriate medication use in elderly inpatients: a pragmatic randomized controlled trial. European Journal of Clinical Pharmacology. 2017. 73(10): 1237-45.
Li G, Thabane L, Delate T, Witt DM, Levine MAH, Cheng J, Holbrook A. Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case. PLoS ONE. 2016. 11(8):e0160713. doi:10.1371/journal.
Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Clinical and Investigative Medicine. 2016. 39 (2):E48-E62.
Kamboj L, Oh P, Levine M, Kammila S, Casey W, Harterre D, Goeree R. Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting. International Journal of Cardiology. 2016;203:893–899.
Hyewon HL, Levine M. Determining the threshold of acceptability of an ICER when natural health units are used. Journal of Population Therapeutics and Clinical Pharmacology. 2012;19(2):e234-8.
Levine MAH, El-Nahas A.I., Asa B. Relative risk and odds ratio data are still portrayed with inappropriate scales in the medical literature. Journal of Clinical Epidemiology. 2010. 63(9)1045-1047.
Singh SR, Levine MAH. Potential Interactions between Pharmaceuticals and Natural Health Products in Canada. Journal of Clinical Pharmacology. 2007. 47:1-10.
Farahani P, Levine M, Gaebel K, LeLorier J, Perreault S, Gillis J, Soon J. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care. Clinical Investigative Medicine. 2007. 30(2)E63-E69.
Farahani P, Levine M, Gaebel K, Thabane L. Clinical Data Gap Between Phase III Clinical Trials (Pre-Marketing) and Phase IV (Post-Marketing) Studies: Evaluation of Etanercept In Rheumatoid Arthritis. Canadian Journal of Clinical Pharmacology. 2005.12(3): e254-e263.
Levine MAH, Gaebel K. A study of patient responses to a perceived change in salbutamol metered dose inhalers. Journal of Generic Medicine. 2005. 2(3):201-208.
- Clinical Pharmacology
- Clinical Epidemiology
- Evidence Based Medicine Methodology